Skip to main content

Table 2 Patient characteristics at baseline (FAS)

From: Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

  Placebo Tofogliflozin
   10 mg 20 mg 40 mg
n 56 57 58 58
Age (years), Mean (SD) 56.8 (9.9) 58.6 (9.8) 56.6 (10.2) 57.0 (9.1)
Gender, n (%) Male 37 (66.1%) 38 (66.7%) 39 (67.2%) 39 (67.2%)
Female 19 (33.9%) 19 (33.3%) 19 (32.8%) 19 (32.8%)
Body weight (kg), Mean (SD) 71.20 (12.64) 67.26 (12.67) 68.06 (15.82) 68.72 (11.91)
BMI (kg/m2), Mean (SD) 26.00 (4.11) 25.07 (3.53) 24.99 (4.55) 25.78 (4.10)
HbA1c (%), Mean (SD) 8.41 (0.78) 8.45 (0.75) 8.34 (0.81) 8.37 (0.77)
Fasting plasma glucose (mg/dL), Mean (SD) 168.8 (24.9) 170.2 (32.4) 168.7 (29.6) 167.9 (37.0)
eGFR (mL/min/1.73 m2), Mean (SD) 83.78 (17.68) 84.90 (20.15) 86.78 (19.62) 86.00 (18.18)
Systolic blood pressure (mmHg), Mean (SD) 128.3 (13.7) 128.0 (15.6) 131.3 (12.9) 129.3 (12.5)
Diastolic blood pressure (mmHg), Mean (SD) 76.7 (11.4) 78.6 (10.6) 79.2 (11.7) 78.7 (9.0)
Duration of diabetes (years), Mean (SD) 6.0 (6.1) 6.3 (7.1) 6.4 (5.1) 6.7 (5.5)
Prior treatment of diabetes Yes 16 (28.6%) 15 (26.3%) 23 (39.7%) 16 (27.6%)
  No 40 (71.4%) 42 (73.7%) 35 (60.3%) 42 (72.4%)
  1. Abbreviations: BMI body mass index, eGFR estimated glomerular filtration rate.